文献速递贫血与红细胞疾病

高剂量静脉铁剂严重过敏反应的系统综述与荟萃分析

Systematic Review and Meta-Analysis of Hypersensitivity Reactions after High-dose Intravenous Iron.
PubMed 文献 · Blood Adv · 2026-09-16

该系统综述与荟萃分析纳入随机对照试验共11,268例缺铁性贫血患者,评估高剂量静脉铁剂FDI、FCM和FER的严重过敏反应发生率。结果显示FDI严重过敏反应发生率为0.14%,低于FCM的0.59%和FER的0.50%;贝叶斯分析提示FDI发生严重过敏反应风险较低,SUCRA显示FDI发生率最低的可能性为91.4%。

要点

  • FDI严重过敏反应发生率为0.14%,FCM为0.59%,FER为0.50%。
  • FDI相比FCM和FER的严重过敏反应风险比分别为0.21和0.07。
  • SUCRA显示FDI严重过敏反应发生率最低的可能性为91.4%。

核心结论

  • 高剂量静脉铁剂中FDI的严重过敏反应发生率最低,FCM最高。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和CENTRAL的随机对照试验,共纳入11,268例患者。

主要发现

  • FDI严重过敏反应发生率为0.14%,FCM为0.59%,FER为0.50%。
  • FDI对比FCM的风险比为0.21(95% CrI 0.03至1.73),对比FER为0.07(95% CrI 0.00至1.93)。
  • SUCRA显示FDI严重过敏反应发生率最低的可能性为91.4%,FCM为4.5%,FER为4.2%。

关键数值与推荐

  • 严重过敏反应依据MedDRA的过敏反应SMQ定义。

临床怎么用

  • 在缺铁性贫血患者选用高剂量静脉铁剂时,FDI可能具有更低的严重过敏反应风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serious or severe hypersensitivity reactions (HSRs) are uncommon with modern intravenous (IV) iron formulations but, when occurring, can be life-threatening or even fatal. We synthesized the available data on serious or severe HSR incidence for ferric derisomaltose (FDI), ferric carboxymaltose (FCM), and ferumoxytol (FER), as treatments for iron deficiency anemia (IDA). A systematic literature review for randomized controlled trials (RCTs) was conducted in PubMed, Embase, and CENTRAL. From eligible RCTs, proportions of patients experiencing serious or severe HSR post-IV iron administration, reported using the Standardized Medical Dictionary for Regulatory Activities Query (SMQ) for anaphylactic reaction, were extracted. A Bayesian random-effects model was used to obtain posterior distributions of HSR incidence and Surface Under the Cumulative Ranking (SUCRA) plots, ranking formulations by HSR likelihood. Any serious or severe HSR falling under the anaphylactic reaction SMQ was experienced by 0.14% of patients with FDI, 0.59% of patients with FCM, and 0.50% of patients with FER. The meta-analysis indicated a reduced serious or severe HSR risk with FDI versus FCM (0.21 [95% credible interval [CrI] 0.03 to 1.73) and FER (0.07 [95% CrI 0.00 to 1.93]). SUCRA plots showed that the likelihood of FDI having the lowest serious or severe HSR incidence was 91.4% (FCM: 4.5%; FER: 4.2%). This meta-analysis of data from RCTs, including 11,268 patients, represents a comprehensive analysis of serious or severe HSRs among the available high-dose IV iron formulations, detailing an important facet of formulations' safety profiles.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Divers S, Elder CT, Foy PC, et al. Systematic Review and Meta-Analysis of Hypersensitivity Reactions after High-dose Intravenous Iron. Blood Adv. 2026. PMID: 42747867. doi:10.1182/bloodadvances.2026019945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。